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Abstract
Heat shock protein (hsp) 90 inhibition attenuates NF-kB activation
and blocks inflammation.However, the precisemechanismofNF-kB
regulation by hsp90 in the endothelium is not clear. We investigated
the mechanisms of hsp90 inhibition by 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG) on NF-kB activation by LPS in
primary human lungmicrovascular endothelial cells. Transcriptional
activation of NF-kB was measured by luciferase reporter assay, gene
expression by real-time RT-PCR, DNA binding of transcription
factors by chromatin immunoprecipitation assay, protein–protein
interaction by coimmunoprecipitation/immunoblotting, histone
deacetylase (HDAC)/histone acetyltransferase enzyme activity by
fluorometry, and nucleosome eviction by partial microccocal DNase
digestion. In human lung microvascular endothelial cells, 17-
AAG–induced degradation of IKBa was accomplished regardless of
the phosphorylation/ubiquitination state of the protein. Hence, 17-
AAG did not block LPS-induced NF-kB nuclear translocation and
DNA binding activity. Instead, 17-AAG blocked the recruitment
of the coactivator, cAMP response element binding protein binding
protein, and prevented the assembly of a transcriptionally competent
RNA polymerase II complex at the kB elements of the IKBa (an NF-
kB–responsive gene) promoter. The effect of LPS on IKBamRNA
expression was associated with rapid deacetylation of histone-H3(Lys9)
and adramatic down-regulationof corehistoneH3binding. Even though
treatment with an HDAC inhibitor produced the same effect as hsp90
inhibition, the effect of 17-AAGwas independentofHDAC.Weconclude
that hsp90 inhibition attenuates NF-kB transcriptional activation by
preventing coactivator recruitment and nucleosome eviction from the
target promoter in human lung endothelial cells.
Keywords: human lung microvascular endothelial cells; heat
shock protein 90 inhibitor; LPS; NF-kB; cAMP response element
binding protein binding protein
Clinical Relevance
NF-kB is a master regulator of inflammation. We report on
a new mechanism regulating NF-kB activity that could reveal
new targets for the management of acute lung injury/acute
respiratory distress syndrome and other pulmonary
inflammatory disease.
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The physical interaction between heat shock
protein (hsp) 90 and its “clients,” which
include transcription factors and protein
kinases (1), is essential for their maturation
and function (2). Disruption of the
hsp90–client interaction results in the
degradation of the client protein (3). Thus,
hsp90 inhibitors have been tested for their
ability to block pathological pathways,
especially in cancer (3). As hsps are also
involved in immune responses (4), they can
be exploited for selectively targeting of
pathways in human immune disorders.
Severe gram-negative bacterial infection
often leads to uncontrolled immune response
as a result of hyperactivated NF-kB signaling
(5). The bacterial endotoxin, LPS, stimulates
Toll-like receptor-4 receptors on the surface of
immune cells and triggers IKKb activation (6).
Activated IKKb, in turn, phosphorylates the
inhibitory IKBa, leading to the degradation of
IKBa (7). After IKBa degradation, NF-kB
dimers are released from the cytosol and
translocated into the nucleus, where they bind
to the kB enhancer element, GGGRNNYYCC
(R = purine, Y = pyrimidine), present on the
promoters of NF-kB–responsive genes and
initiate transcription (8). NF-kB
hyperactivation in the lung endothelium after
severe bacterial septicemia, is a fundamental
step in the development of acute inflammatory
lung diseases (9, 10). The role of NF-kB
activation in endothelial cells is twofold. First,
it elicits proinflammatory cytokine production,
and second, it accelerates leukocyte infiltration
by inducing cell adhesion molecules (6).
Several key regulators of Toll-like receptor-4
receptor pathway, such as TAK-1 kinase, RIP
kinase, and IkB kinases are clients of hsp90
(1), suggesting that the NF-kB pathway could
be highly sensitive to hsp90 inhibitors, such as
17-N-allylamino-17-demethoxygeldanamycin
(17-AAG), which has been demonstrated to be
highly specific to hsp90 in numerous reports (11).
Inhibition of hsp90 evokes complex
NF-kB regulation. In tumor, vascular
smooth muscle, and macrophage cells,
hsp90 inhibition blocks NF-kB signaling by
suppressing its nuclear translocation
(12–15). Hsp90 inhibition also blocks
mitogen-activated protein kinase pathway
activation in mice (16) and NF-kB post-
translational modifications in mouse
macrophages (17). In yeast, inhibition of
the hsp90/hsp70 chaperone complex by
genetic manipulation blocks nucleosome
eviction from a transcriptionally competent
promoter (18). However, the precise
mechanism of hsp90 in endothelial NF-kB
hyperactivation is still not clearly understood.
In this study, we investigated three distinct
mechanisms that may be responsible for hsp90
regulation of LPS-induced NF-kB activation in
human lung microvascular endothelial cells
(HLMVECs): NF-kB nuclear translocation,
cAMP response element binding protein
binding protein (CBP) coactivator
recruitment, and nucleosome reorganization.
Materials and Methods
Reagents and Antibodies
Escherichia coli endotoxin (LPS) L-3137
was purchased from Sigma-Aldrich (St.
Louis, MO). 17-AAG was from Selleck
Chemicals (Houston, TX). All other
inhibitors were purchased from ENZO Life
Sciences (Farmingdale, NY). Anti-IKBa and
anti–phospho-IKBa (Ser32/36) antibodies
were from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti–acetyl-H3(Lys9), anti-H3,
anti-HA, anti–Poly-(ADP-ribose)
polymerase and anti–Lamin-associated
protein 2a antibodies were from Cell
Signaling Technology (Danvers, MA). Anti-
p65, anti-CBP, and anti-ubiquitin antibodies
were from Abcam (Cambridge, MA).
Anti–phospho-RNA polymerase (Pol) II Ser5
antibody was from Active Motif (Carslbad,
CA). Anti–b-actin and horseradish
peroxidase–conjugated secondary antibodies
(mouse and rabbit IgG) were from Sigma
Aldrich. a-Tubulin antibody was from
Covance Research Products (Denver, PA).
Cell Culture and Treatment
Primary cultures of HLMVECswere harvested,
isolated, and cultured in house, as previously
described (19).
Western blotting and
coimmunoprecipitation were performed as
previously described (20).
Adenoviral Transduction and NF-kB
Luciferase Reporter Assay
NF-kB firefly luciferase (Luc) reporter
adenovirus was obtained from Vector Biolabs
(Philadelphia, PA). Green fluorescent protein
(GFP)-expressing adenovirus was generated
and characterized as described previously (21).
HLMVECs were cotransduced with NF-
kB–Luc (10 MOI) and GFP (100 MOI) in 96-
well plates for 3 days, then treated with 1 EU/
ml LPS for 4 hours in the presence and
absence of 17-AAG (5 mg/ml, 16 h). Equal
amounts of the lysate were used in duplicates
for determining GFP fluorescence (485/528
nm) using a Biotek Synergy HT microplate
reader (Winooski, VT). Luminescence was
measured using the Bright Glo Luc reagent
(Promega, Madison, WI) with GloMax
luminometer (Promega) and normalized to
GFP fluorescence.
Transfection
HLMVECs were transfected with
cytomegalovirus promoter driven mammalian
expression plamids–3HA-IKBa or IKBaSer32/
36(alanine [Ala]/Ala) double mutant,
purchased from Addgene (Cambridge, MA),
using Effectene transfection reagent
(QIAGEN, Valencia, CA). HLMVECs were
grown in 100-mm dishes and transfected with
2.5 mg plasmid mixed with 60 ml of the
transfection reagent. After 3 days, the cells
were treated with LPS (1 EU/ml) for 1 hour in
the presence or absence of 17-AAG (16 h).
IKBa expression levels were assessed by
Western blotting using anti-HA antibody
(Cell Signaling Technology).
Microccocal DNase Assay
Treated HLMVECs were fixed in 1%
formaldehyde for 10 minutes and blocked with
125 mM glycine for 5 minutes at room
temperature. The cells were washed 33
with chilled PBS, resuspended in 10 mM
Hepes (pH 8) buffer, containing 3 mMMgCl2,
10 mM KCl, 0.5% Nonidet-P40, 1 mM DTT,
1 mM PMSF, and protease inhibitor, and
incubated for 10 minutes on ice. The
suspension was partially digested with 50 EU
microccocal DNase (New England Biolabs,
Ipswich, MA) in 0.1 ml 13 digestion buffer
supplemented with 100 mg/ml BSA and 0.1%
Triton X-100 for 5 minutes at 378C. The
reaction was stopped by adding 0.1 ml 100
mM Tris-HCl (pH 8), containing 20 mM
EDTA, 4% SDS, and 400 mM NaCl. The
mixture was incubated for 10 hours at 658C to
reverse cross-linking, and DNA was isolated
using PrepEase DNA columns (Affymetrix,
Santa Clara, CA). Eluted DNA (20 ng) was
used to PCR amplify the IKBa promoter,
and was normalized to glyceraldehyde
3-phosphate dehydrogenase.
Statistical Analysis
Data represent more than three separate
experiments and are reported as means
(6 SE). Differences among groups were
analyzed using one-way ANOVA and post hoc
tested with the Tukey-Kramer multiple
comparison test. The t test for independent
samples was used for comparisons between
two groups. Significance was accepted at
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P less than 0.05. Statistical calculations
were performed using GraphPad Prism 5
(GraphPad Software, Inc., La Jolla, CA).
Results
The hsp90 Inhibitor, 17-AAG, Blocks
LPS-Induced IKBa Phosphorylation
and Ubiquitination, but Not
Degradation, in HLMVECs
Short-term (2-h) 17-AAG treatment had no
effect on LPS-induced IKKb activation, but
16-hour treatment significantly reduced
IKKb activation (Figure 1A). Furthermore,
only 16-hour 17-AAG treatment blocked
LPS-induced IKBa phosphorylation, but
failed to prevent LPS-induced IKBa
degradation (Figure 1B). This was not due
to suboptimal inhibition of hsp90 by
17-AAG by a short-term treatment, as
both 2- and 16-hour treatments blocked
extracellular signal–regulated kinase 1/2
mitogen-activated protein kinase activation
by LPS to a similar extent (Figure 1B). In
addition, there was a dramatic induction of
hsp70 mRNA expression by 2-hour 17-
AAG treatment (see Figures E1 and E2 in
the online supplement), and a modest
increase in hsp70 protein expression
(Figure 1B). The synergistic effect of LPS
and 17-AAG on IKBa degradation was
partially blocked by the proteasomal
inhibitor, PS-341 (Figure 1C). In addition,
the degradation of IKBa in the presence of
17-AAG was not due to residual IKK
activity, as it was not affected by the IKK
Figure 1. The heat shock protein (hsp) 90 inhibitor, 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), abolishes LPS-induced IKBa phosphorylation, but does not
prevent IKBa degradation. Human lung microvascular endothelial cells (HLMVECs) were pretreated for 2 or 16 hours with 5 mg/ml 17-AAG followed by LPS (1 EU/ml)
for 15 minutes, and IKKb activation was determined by ELISA. Only the long-term (16-h) 17-AAG pretreatment significantly blocked IKKb activation (A) (***P , 0.001).
Means 6 SE of vehicle fold activated IKKb from three independent experiments. Both 2- and 16-hour 17-AAG treatment blocked the LPS-mediated extracellular
signal–regulated kinase (ERK) 1/2 mitogen-activated protein kinase (MAPK) phosphorylation, and produced a gradual induction of hsp70 expression in HLMVECs.
However, only the 16-hour 17-AAG treatment blocked LPS (1 EU/ml, 1 h) -induced IKBa phosphorylation, but did not prevent it’s degradation (B). The figure is
representative of one of the three independent experiments; a histogram of IKBa regulation by 17-AAG is presented in Figure E1A. The synergism between 17-AAG and
LPS was attenuated by the 26S proteasomal inhibitor, PS-341 (1 mM for 1 h; compare lanes 6 and 8 [C]; *P , 0.05 and ***P , 0.001). Residual IKKb activity was
not responsible for the LPS 1 17-AAG–induced IKBa degradation, as the IKK inhibitor, IKK16 (5 nM for 1 h), administered after 16-hour exposure of HLMVECs to
17-AAG, could not restore IKBa protein levels after LPS stimulation (compare lanes 4 and 8 [D]). To confirm that 17-AAG induces degradation of nonphosphorylated IKBa,
the HA-tagged phosphorylation-deficient IKBa Ser32/36 (Ala/Ala) double mutant was overexpressed in HLMVECs. The cells were then treated with LPS for 1 hour in the
presence and absence of 17-AAG (16 h). In the presence of LPS, 17-AAG promoted the degradation of the IKBa double mutant in HLMVECs (E).
ORIGINAL RESEARCH
944 American Journal of Respiratory Cell and Molecular Biology Volume 50 Number 5 | May 2014
inhibitor, IKK16, administered after
17-AAG (Figure 1D).
NF-kB–associated IKBa has a longer
half-life compared with free IKBa (22).
Thus, we tested the hypothesis that
hsp90 inhibition may destabilize this
interaction and promote IKBa
degradation by LPS. 17-AAG destabilized
the association of IKBa with p65 in
LPS-stimulated HLMVECs (Figure E3).
Because 17-AAG did not block the
LPS-induced degradation of IKBa, we
expected that it might not affect the LPS-
induced ubiquitination of IKBa, as well.
Surprisingly, inhibition of hsp90
suppressed IKBa phosphorylation as well
as IKBa poly-ubiquitination (Figure E4).
This suggested that, contrary to accepted
theory, hsp90 inhibition promotes the
degradation of nonphosphorylated IKBa.
To confirm this, we overexpressed HA-
tagged wild-type and phosphorylation-
deficient IKBaSer32/36(Ala/Ala) in
HLMVECs and exposed them to LPS in
the presence and absence of 17-AAG.
The phosphorylation-deficient IKBa was
not affected by LPS alone, but was
profoundly degraded in the presence
of both LPS and 17-AAG (Figures 1E
and E5).
The hsp90 Inhibitor, 17-AAG, Does
Not Prevent the LPS-Induced Nuclear
Translocation of NF-kB (p65)
in HLMVECs
Once released from IKBa, NF-kB rapidly
translocates into the nucleus and binds kB
enhancer elements in target promoters. We
tested whether 17-AAG blocks the nuclear
translocation of NF-kB and modulates the
DNA binding affinity of NF-kB proteins.
17-AAG did not affect LPS-induced p65 or
p50 nuclear translocation (Figure 2A). Also
the DNA-binding affinity of p65 (as
measured by ELISA) was similar between
LPS and LPS plus 17-AAG–treated
Figure 2. The hsp90 inhibitor, 17-AAG, prevents NF-kB transcriptional activation without interfering with NF-kB nuclear translocation and intrinsic DNA
binding. HLMVECs were treated with LPS for 1 hour in the presence or absence of 17-AAG (16 h). NF-kB nuclear translocation was assessed by p65
and p50 immunoblotting. The LPS-induced nuclear translocation of NF-kB was not prevented by 17-AAG (A); *P , 0.05 and **P , 0.01. The LPS-
induced DNA binding efficiency of p65 was also assessed in the presence or absence of 17-AAG by the TransAM NF-kB p65 kit (Active Motif). 17-AAG
did not reduce the LPS-induced p65 DNA binding in HLMVECs (B); means 6 SE of vehicle-fold p65 DNA binding from three independent experiments,
each done in duplicate; ***P , 0.001. However, chromatin immunoprecipitation (ChIP) assay of p65/RelA and p50 showed that LPS (10 EU/ml, 1 h)
induced binding to the IKBa promoter that was abolished by 17-AAG (P , 0.01) (C). The HIF-1a enhancer site in the human VEGF promoter served
as the negative control for the assay. Means 6 SE of three independent experiments.
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HLMVECs (Figure 2B). To confirm that
this observation was unique to HLMVECs,
these experiments were repeated in bovine
pulmonary arterial endothelial cells. As
previously reported in other tissues, hsp90
inhibition prevented both the LPS-induced
nuclear translocation of p65 (Figure E6)
and p65 binding to DNA (Figure E7). We
then studied the effect of 17-AAG on
NF-kB binding to the IKBa (an NF-kB
target gene) promoter by chromatin
immunoprecipitation (ChIP) assay. We
found that 17-AAG attenuated the LPS-
stimulated p65 and p50 binding to the
IKBa promoter (Figure 2C). Real-time
quantitative RT-PCR confirmed that 17-
AAG blocked the induction of three NF-kB
target genes (IKBa, IL-8, and matrix
metalloproteinase-9) by LPS (Figure E8).
This suggested that the inhibition of hsp90
might regulate the transcriptional activation
of NF-kB by regulating the accessibility of
NF-kB to the target promoter.
To confirm the effect of 17-AAG on
LPS-induced NF-kB transcriptional
activation, an NF-kB Luc reporter and GFP
were overexpressed in HLMVECs. NF-kB
reporter assay was performed in triplicate
and normalized to the corresponding GFP
fluorescence. 17-AAG abolished the LPS-
induced Luc activity (Figure 3A). In
addition, short hairpin RNA–mediated
knockdown of hsp90 similarly blocked LPS-
induced NF-kB reporter activation
(Figure 3B), and concomitantly increased
hsp70 expression, a hallmark of hsp90
inhibition. Furthermore, the overexpression
of hsp90a overcame the inhibitory effect of
17-AAG on LPS-induced NF-kB reporter
activation (Figure 3C). These results
suggested that the effect of 17-AAG was
due to specific inhibition of hsp90.
LPS Suppresses Histone-H3(Lys9)
Acetylation and Down-Regulates
Core Histone H3 Binding to the
IKBa Promoter
Nucleosome reorganization during
transcription initiation determines the
accessibility of transcription factors to their
cognate enhancer elements (23). To study
whether the observed effects of hsp90
inhibitors on NF-kB target gene activation
involve regulation of nucleosome
Figure 3. The hsp90 inhibitor, 17-AAG, blocks NF-kB transcriptional activity. HLMVECs were infected with an adenoviral NF-kB luciferase (Luc) reporter
together with a green fluorescent protein (GFP) adenovirus (Adeno) 72 hours before a 4-hour exposure to LPS (10 EU/ml) in the presence and absence
of 17-AAG (5 mg/ml, 16 h). 17-AAG blocked the LPS-induced NF-kB reporter activation (A); ***P , 0.0001. To confirm the role of hsp90 in the
regulation of NF-kB transcriptional activation, endogenous hsp90 was depleted by hsp90 short hairpin RNA (shRNA) lentivirus in HLMVECs, as described
in the MATERIALS AND METHODS in the online supplement. Hsp90 protein down-regulation by shRNA compared with the control shRNA and the associated
hsp70 up-regulation is shown in the upper panels of (B) (the images are cropped from the same gel for better representation). The middle panels
shows the histogram of means 6 SE of fold protein from triplicate experiments (***P , 0.001). The lower panels shows that hsp90 down-regulation
blocked NF-kB Luc reporter activation by LPS (*P , 0.05). On the other hand, the overexpression of Adeno–hsp90a reversed the inhibition of NF-kB Luc
reporter activity by 17-AAG (C). The upper panel shows the overexpression of Adeno-hsp90a and the lower panel shows the histogram of fold NF-kB
activation (means 6 SE of triplicates; **P , 0.01, ***P , 0.001). The experiments were repeated three times.
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reorganization, we studied the proximal
roughly 0.5-Kb 59-untranslated region of
the IKBa promoter by ChIP assay. The
IKBa promoter was associated with histone
H3 and was constitutively acetylated at
(Lys9) in HLMVECs (Figure 4A). LPS
induced a concentration-dependent
deacetylation of histone H3 (Lys9) and H3
displacement from the promoter region
(Figure 4A). The H3 (Lys9) deacetylation
and H3 displacement were specific to the
IKBa promoter and was observed neither
in the b-actin promoter, which is not
regulated by LPS (Figure 4B), nor in the
SOCS3 promoter, which is not a target of
NF-kB, but is regulated by LPS (Figure 4C).
Furthermore, LPS induced H3 Lys9
deacetylation in the total histone extract
without affecting acetylation at Lys14
(Figure 4D).
Either Histone Deacetylase or hsp90
Inhibitor Prevent the LPS-Induced
Displacement of Nucleosome from
the IKBa Promoter in HLMVECs
Histone acetyltransferases and histone
deacetylases (HDACs) regulate the
acetylation of both histones and nonhistone
proteins (24). Because LPS-mediated
NF-kB activation involves histone
deacetylation, we tested the role of HDAC
using the inhibitor, trichostatin A (TSA).
TSA blocked the LPS-induced IKBa and
IL-8 mRNA expression in HLMVECs
(Figure E9). TSA also attenuated p65
binding to the IKBa promoter (Figure 5A).
We also tested the effect of TSA on histone
H3 (Lys9) deacetylation and core H3
displacement. Somehow, TSA did not
restore H3 (Lys9) acetylation at the IKBa
promoter; however, TSA effectively blocked
the LPS-induced core H3 displacement
from the IKBa promoter (Figure 5B).
To study whether the effect of hsp90
inhibition was via an epigenetic mechanism,
we tested the effect of 17-AAG on
nucleosome reorganization and core histone
modification at the IKBa promoter by ChIP
assay. 17-AAG significantly reduced the
LPS-mediated H3 (Lys9) deacetylation
and H3 displacement in HLMVECs
(Figure 5C). Because both TSA and 17-
AAG affected NF-kB binding and core
histone displacement, we investigated
Figure 4. LPS suppresses histone-H3(Lys9) acetylation and down-regulates core histone H3 binding to the IKBa promoter. HLMVECs were treated for
1 hour with increasing concentrations of LPS (0.1–10 EU/ml). The regulation of core histone H3 at the IKBa promoter was assessed by ChIP assay.
LPS induced a concentration-dependent deacetylation of H3 and binding of core H3 to the IKBa promoter (A). Mean 6 SE of three experiments
(*P , 0.05, **P , 0.01). This regulation of core histone H3 by LPS was not observed in non–NF-kB target gene promoters, b-actin (B) and SOCS3 (C).
Furthermore, immunoblotting of total histone extract demonstrated that Lys9 deacetylation was specific to H3 (Lys9), as deacetylation of H3 (Lys 14)
was not observed in LPS-treated HLMVECs (D).
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whether hsp90 inhibition and HDAC
inhibition shared a common mechanism.
The partial micrococcal DNase assay
demonstrated that both 17-AAG and TSA
attenuated LPS-induced DNase
hypersensitivity, albeit to different extents
(Figure 5D). 17-AAG blocked the LPS
effect, whereas TSA produced a partial
attenuation. To determine whether hsp90
inhibition acted via HDAC inhibition, we
sudied the effect of 17-AAG on LPS-
induced HDAC activation. 17-AAG did not
affect LPS-induced HDAC activation
(Figure E10). This suggests that hsp90
inhibitors work through an alternate
pathway of H3 deacetylation, and possibly
regulate nucleosomal reorganization via
mechanisms other than HDAC inhibition.
The hsp90 Inhibitor, 17-AAG,
Attenuates CBP/HAT Activity and
Prevents Its Recruitment to the
IKBa Promoter
Because 17-AAG did not alter HDAC
activity, we considered that it could prevent
the LPS-induced activation of histone
acetyltransferases. LPS alone induced
nuclear HAT activation and 17-AAG
blocked this activation (Figure 6A).
NF-kB employs several cofactors for
transcriptional activation of target genes,
including CBP/p300 and PCAF (25). CBP
belongs to a family of HAT, and regulates
NF-kB–responsive gene expression (26).
Thus, we used immunoprecipitated CBP
from nuclear lysates to test the hypothesis
that 17-AAG prevents LPS-stimulated
CBP/HAT activation. LPS induced CBP
activation and 17-AAG attenuated the
Figure 5. Both histone deacetylase (HDAC) and hsp90 inhibition down-regulate LPS-mediated NF-kB activation in HLMVECs. HLMVECs were treated
with LPS (4 h, 10 EU/ml) in the presence or absence of the HDAC inhibitor, trichostatin A (TSA; 1 mM for 1 h) or 17-AAG (5 mg/ml for 16 h). TSA also
blocked the LPS-induced p65 binding to the IKBa promoter (*P , 0.5) (A), and prevented the LPS-induced core histone H3 displacement from the IKBa
promoter (*P , 0.01). However, TSA did not prevent the LPS-induced deacetylation of promoter-associated H3 (Lys9) (P , 0.05) (B). ChIP assay
demonstrated that, unlike TSA, 17-AAG blocked both the deacetylation of H3 (Lys9), as well as the displacement of core H3 from the IKBa promoter (C).
However, both HDAC and hsp90 inhibitors block the LPS-induced hypersensitivity of IKBa promoter to microccocal DNase (MNase) (D). The upper panel
in (B) shows the inverted image of a representative PCR-amplified IKBa promoter after partial MNase digestion. The lower panel in (B) depicts means 6
SE of three experiments. 17-AAG completely prevented the effect of LPS (**P , 0.01), whereas TSA only partially blocked MNase hypersensitivity.
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activation in a concentration-dependent
manner (Figure 6B). Furthermore, the
physical interaction between p65 and CBP
is considered to be important for NF-kB
activity and gene induction (26). Thus, in
coimmunoprecipitation studies, we
examined the interaction of p65 and CBP. LPS
induced CBP/p65 association in HLMVEC
nuclear extracts, and 17-AAG suppressed this
interaction (Figure 6C). We also tested the
recruitment of CBP to the IKBa promoter,
and observed that 17-AAG blocked the LPS-
induced recruitment of CBP (Figure 6D).
Ser276 phosphorylation of p65 by
mitogen and stress activated kinase-1 and
cAMP-dependent protein kinase promotes
the interaction and recruitment of CBP to
target promoters (27–29). Thus, we
investigated the effect of 17-AAG on the
LPS-induced p65 (Ser276) phosphorylation
in HLMVECs. LPS induced p65 Ser276
phosphorylation, and this was attenuated
by hsp90 inhibition (Figure E11). We then
overexpressed adenoviral p65 wild type and
Ser276→Asp mutant in HLMVECs and
examined the LPS-mediated activation of
NF-kB Luc reporter. The phosphomimic
did not prevent the 17-AAG–mediated
attenuation of the LPS-stimulated NF-kB
reporter activity (Figure E12). This suggests
that p65Ser276 phosphorylation does not
play a significant role in NF-kB regulation
by 17-AAG, and is unlikely to be involved
in the recruitment of CBP by p65.
The recruitment of CBP by p65
promotes cooperative binding of NF-kB to
multiple elements (26). This, in turn,
induces an optimal DNA conformation for
subsequent downstream events, such as
binding of nucleosome remodeling
enzymes and other factors that regulate the
transcription of inducible genes (30). Ser5-
phosphorylated RNA Pol II is important for
initiation of transcription, and Ser5
phosphorylation increases enzyme activity
(31). We thus examined, by ChIP assay,
whether hsp90 inhibition prevents the
assembly of a functional RNA Pol II
Figure 6. The hsp90 inhibitor, 17-AAG, blocks LPS-induced CBP/histone acetyltransferase (HAT) activation and recruitment to the IKBa promoter.
HLMVECs were treated with LPS (10 EU/ml, 1 h) in the presence and absence of 17-AAG (16 h). Nuclear extracts were used to estimate total nuclear HAT
activity and CBP activity using the HAT activity assay kit. 17-AAG attenuated the LPS-induced total HAT activation (A) (***P , 0.0001) and blocked the
LPS-induced nuclear CBP activation in a concentration-dependent manner (B) (**P , 0.01). Means 6 SE of three independent experiments, each
performed in duplicate. In addition, CBP protein was immunoprecipitated from HLMVEC nuclear extracts, and its association with p65 was investigated by
Western blotting. LPS induced an association between CBP and p65 that was prevented by 17-AAG (C). We also checked the recruitment of CBP to
the IKBa promoter by ChIP assay. LPS (10 EU/ml, 15 min) promoted CBP binding to the IKBa promoter, and 17-AAG (5 mg/ml, 16 h) blocked this
binding (D) (**P , 0.01). Means 6 SE of three experiments (*P , 0.05).
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complex at the IKBa promoter of
HLMVECs. LPS induced the
phosphorylation of RNA Pol II Ser5 at the
IKBa promoter; this phosphorylation event
was attenuated by 17-AAG (Figure 7A). As
a control, we also studied the b-actin
promoter. RNA Pol II was hyperactivated
in the constitutively active b-actin
promoter, and the level of Ser5
phosphorylated RNA Pol II was high. No
additional stimulation/phosphorylation by
LPS was observed, and no attenuation by
17-AAG. Similarly, no change in RNA Pol
II Ser5 phosphorylation was observed in the
SOCS3 promoter under these conditions.
These findings suggest that 17-AAG
attenuated LPS-mediated RNA Pol II
complex assembly specifically at the
NF-kB–responsive IKBa promoter.
Discussion
NF-kB activation is regulated at multiple
steps: nuclear translocation, post-
translational modification, and chromatin
remodeling at the promoter region (32, 33).
Our data suggest that, in HLMVECs, hsp90
inhibition blocks IKKb activation
and IKBa phosphorylation and
polyubiquitination by LPS (canonical
pathway), but cannot prevent IKBa
degradation. Crystal structure (22) and
thermodynamic studies have revealed an
interaction between NF-kB and IKBa (34)
that is responsible for the difference in the
turnover rate between the bound and free
IKBa (34, 35). Any modification that
destabilizes this interaction promotes IKBa
degradation. The destabilization of IKBa by
17-AAG in LPS-stimulated HLMVECs
could be due to reduced binding of IKBa to
p65.
Hsp90 inhibition did not affect DNA
binding affinity of NF-kB/p65. However, it
blocked its binding to the IKBa promoter.
Free NF-kB binds cognate elements inside
the nucleus. However, in most cases,
multiple kB elements need to be occupied
before transcriptional induction. The
human IKBa promoter has three critical
NF-kB consensus sites in the proximal
Figure 7. The hsp90 inhibitor, 17-AAG, prevents the assembly of RNA polymerase (Pol) II complex at the IKBa promoter. To study whether 17-AAG
affected the assembly of an active RNA Pol II complex at the IKBa promoter, ChIP assay of phosphor-RNA Pol II Ser5 was performed in HLMVECs. LPS
induced binding of phosphor-RNA Pol II Ser5 on the IKBa promoter, and this was prevented by 17-AAG. The effects of LPS and 17-AAG were unique for
the IKBa promoter and not observed at the actin and SOCS3 promoters, which are insensitive to LPS and NF-kB, respectively. Means 6 SE of three
experimental repeats (A); *P , 0.05). (B) The proposed model of hsp90 regulation of LPS-stimulated NF-kB transcriptional activation in HLMVECs. Under
physiologic conditions, nucleosome-associated kB enhancer in the promoter is not accessible for NF-kB binding. LPS displaces core histones that
unmask kB enhancer elements. Recruitment of CBP by p65 stabilizes the NF-kB/enhancer complex and, at the same time, promotes its interaction with
RNA Pol II. The inhibition of hsp90 by 17-AAG blocks core histone displacement and prevents CBP recruitment, thereby terminating transcriptional
initiation of NF-kB target genes by LPS.
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500 bp of the 59-untranslated region (36).
The accessibility of NF-kB to these sites is
determined by DNA conformation and the
presence or absence of core histones.
Eukaryotic DNA is packed into chromatins
composed of repeated units of 147 bp DNA
tightly wound around the histone octamer.
These nucleosomes render most elements
inaccessible to transcription factors. During
gene transcription, nucleosomes are believed
to slide along the DNA by an ATP-
dependent remodeling process (37).
Although certain NF-kB–mediated
transcription does not require nucleosomal
remodeling (33), we now demonstrate that
nucleosome remodeling and displacement of
core histone H3 from the IKBa promoter is
a key mechanism of LPS-induced NF-kB
transcriptional activation in HLMVECs.
Furthermore, the displacement of histone H3
was associated with specific deacetylation of
H3 (Lys9), suggesting the involvement of
HDAC. Our data indicate that hsp90
inhibition and HDAC inhibition regulate
NF-kB activation differently. For example, the
inhibition of HDAC by TSA did not restore
promoter-associated H3 (Lys9) acetylation,
but blocked core histone H3 displacement by
LPS. On the other hand, 17-AAG blocked
both H3 (Lys9) deacetylation and H3
displacement from the IKBa promoter.
The role of hsp90 in chromatin
remodeling was demonstrated in yeast,
where deletion of either hsp70 or hsp90
chaperone suppressed nucleosome eviction
from the actively transcribing galactose
inducible promoter 1 (GAL1) promoter.
The yeast orthologs of hsp70 and hsp90 are
recruited to GAL1 promoter on induction,
and their deletion prevents transcription, in
the absence of any defects in galactose
signaling and GAL4 DNA binding (18).
Our data also suggest that hsp90 inhibition
by 17-AAG prevented LPS-mediated NF-
kB target gene expression without affecting
NF-kB nuclear translocation and DNA
binding. We then demonstrated that the
suppression of transcription is due to
failure of nucleosome eviction and core
histone displacement from the IKBa
promoter. Nuclear actions of Hsp90 have
been reported before. Hsp90 nuclear
shuttling has been observed in yeast; also,
hsp90 complexes with the immature steroid
receptor and shuttles between the
cytoplasm and the nucleus (38). Thus,
hsp90 is likely to play a key role in nuclear
events, such as nucleosome remodeling
during transcription initiation.
The binding of NF-kB/p65 to the
coactivator, CBP, and its recruitment to the
target promoter has a profound effect on
the transcriptional activation of NF-
kB–responsive genes. CBP is a HAT, and
modifies both histone and nonhistone
proteins (39). LPS promoted p65
interaction with CBP and recruitment to
the IKBa promoter. On the other hand, 17-
AAG abolished CBP recruitment, and this
is likely due to the prevention of p65
binding to the IKBa promoter. As p65
binding to promoter is obligatory for CBP
recruitment (25, 27, 29), the down-
regulation of CBP binding by 17-AAG may
not appear to explain the attenuation of
NF-kB binding to IKBa promoter (Figures
2D and 2E). On the other hand, cofactor
binding is known to promote the
cooperative binding of transcription factors
to multiple enhancer elements (33). Thus, we
propose that the lack of CBP recruitment to
the IKBa promoter on hsp90 inhibition most
likely precludes NF-kB binding to all
enhancer elements in the IKBa promoter,
and thereby effectively lowers the promoter
binding efficiency of NF-kB.
Coactivator recruitment by NF-kB is
also important for assembly of active
transcriptional machinery on the RNA Poll
II preinitiation complex. CBP directly
interacts with p65 as well as several
members of the basal transcriptional
complex, such as TATA binding protein,
transcription factor IIB, and RNA Poll II
(30). Thus, CBP acts as a bridge between
the activator complex and the basic
transcription machinery. We now
demonstrate that hsp90 inhibition also
prevents the LPS-induced formation of an
active RNA Pol II complex at the IKBa
promoter. Thus, the attenuation of CBP
recruitment in the presence of 17-AAG
could be one of the mechanisms for
suppression of LPS-mediated NF-kB
transcriptional activation in HLMVECs.
The overall scheme of NF-kB
transcriptional regulation by hsp90
inhibition in HLMVECs is depicted in
Figure 7B.
In conclusion, we propose that hsp90
inhibition not only affects cytosolic
signaling pathways, but also influences the
reorganization of nucleosomes during
transcriptional activation of NF-kB. Thus,
the versatile property of hsp90 inhibitors,
such as 17-AAG, could be exploited to
effectively target the NF-kB signaling
pathway and develop novel, potent anti-
inflammatory drugs for acute inflammatory
diseases. n
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